Related Articles
Irinotecan monotherapy offers advantage over combination therapy with irinotecan plus cisplatin in second-line setting for treatment of advanced gastric cancer following failure of fluoropyrimidine-based regimens
Impact of the availability of active cytotoxic agents on the survival of patients with advanced gastric cancer
Weekly vs. 3‑weekly paclitaxel, carboplatin, and cetuximab (PCC) in recurrent/metastatic head and neck cancer
Cetuximab retreatment in patients with metastatic colorectal cancer who exhibited a clinical benefit in response to prior cetuximab: A retrospective study
Efficacy of weekly paclitaxel treatment as a single agent chemotherapy following first-line cisplatin treatment in urothelial bladder cancer